Found 5 resultsAuthor [ Title] Type Year
Filters: First Letter Of Title is P and Author is Lindblad, R [Clear All Filters]
A Phase 1 Study of Heat/Phenol Killed, E. coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy. In AAAAI - American Academy of Allergy, Asthma & Immunology (Vol. 129(2), p. AB27). presented at the 15/02/2012, Orlando, FL: Journal of Allergy and Clinical Immunology Vol. 129, Issue 2, Supplement, Page AB27. Retrieved from http://download.journals.elsevierhealth.com/pdfs/journals/0091-6749/PIIS0091674911027278.pdf. (2012).
A Phase 1 Study of Heat/Phenol-Killed, E. coli - Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy. Allergy, 68, 803-808. presented at the 06/2013. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23621498. (2013).
A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy, 68(6), 803-8. presented at the 2013 Jun. doi:10.1111/all.12158. (2013).
Production Assistance for Cellular Therapies (PACT): Four-Year Experience from the United States National Heart, Lung, and Blood Institute (NHLBI) Contract Research Program in Cell and Tissue Therapies. Transfusion, 49, 786-796. presented at the 04/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed?term=19170985. (2009).